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Schizophrenia: limitations with currently available drugs Schizophrenia is a chronic debilitating mental disorder that affects approximately 1% of the general population. Symptoms vary from patient to patient but are generally categorized into positive (e.g., hallucinations, delusions, and disorganized speech and behavior), negative (e.g., social withdrawal, lack of motivation, flat affect), and cognitive (e.g., impairments in memory, attention, and executive function). These symptoms are typically associated with social and/or occupational dysfunction. Although the natural course is heterogeneous, the illness typically strikes in late adolescence or early adulthood and usually continues throughout life [1, 2] . The prognosis of patients is also variable, but is often poor, with high rates of unemployment, homelessness, violence, and suicide [3, 4] . Given the combination of onset in early adulthood and the chronic course, schizophrenia presents a staggering drag on the economy and society. It has been estimated that the cost of schizophrenia in the USA in 2002 exceeded $62 billion [5] and the World Health Organization ranks this disorder among the top 10 causes of disability in developed countries [6] .
The classical dopamine (DA) hypothesis (see Glossary) has dominated the theories of schizophrenia since the mid20th century after the observation that first-generation, or 'typical', antipsychotic drugs, such as chlorpromazine and haloperidol, are high-affinity antagonists of dopamine D 2 receptors. Hyperactivity in the mesolimbic DA pathway was originally proposed to underlie positive symptoms of schizophrenia [7] . While effective against positive symptoms, typical antipsychotic drugs demonstrate limited efficacy against negative symptoms and cognitive impairments which have been shown to contribute to functional impairment and predict poor prognosis [8] . Moreover, these
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Glossary
Allosteric site: a binding site on a receptor macromolecule that is nonoverlapping and spatially distinct from, but conformationally linked to, the orthosteric binding site. Dopamine (DA) hypothesis: the most classical schizophrenia hypothesis that attributes psychotic symptoms to hyperactive DA signaling in the brain. Epigenetics: literally means 'above' or 'on top of' genetics. It refers to external modifications to DNA that turn genes 'on' or 'off' without changes in DNA sequence. Excitatory postsynaptic potential (EPSP): a temporary depolarization of postsynaptic neuron membrane potential that makes it more likely that this neuron will trigger an action potential. Glutamate: the main excitatory neurotransmitter in the brain. G-protein-coupled receptor (GPCR): an integral plasma membrane protein that senses molecules outside the cell and transduces those extracellular signals to intracellular relay proteins, the heterotrimeric GTP-binding proteins (G proteins). Heteromer: structural assembly composed of two or more different components. Histone: evolutionarily conserved proteins found in eukaryotic cell nuclei that package DNA into structural units termed nucleosomes. Covalent modifications at the N-terminal tail of histones correlate with open or closed states of chromatin, depending on the type of modification, and thus lead to changes in gene expression. Histone deacetylase (HDAC): a class of enzymes that remove acetyl groups from histones, allowing the histones to wrap the DNA more tightly and repress gene transcription. Metabotropic glutamate receptors (mGluRs): GPCRs that bind glutamate and function to modulate, rather than mediate, synaptic transmission. This is to differentiate them from 'ionotropic' glutamate receptors, such as NMDA receptors, which are ion channels mediating excitatory neurotransmission. N-methyl-D-aspartate (NMDA) receptor: a glutamate receptor and ion channel protein found in nerve cells. It is involved in synaptic transmission and plays an important role in learning and memory. NMDA hypofunction hypothesis: a glutamate-based hypothesis which postulates that reduced NMDA glutamate receptor activation underlies the development of different schizophrenia symptoms. Orthosteric site: the binding site on a receptor macromolecule that is recognized by the endogenous agonist for that receptor. 
